Fuan Pharmaceutical Group Co
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, generic drugs, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and… Read more
Fuan Pharmaceutical Group Co (300194) - Net Assets
Latest net assets as of September 2025: CN¥4.45 Billion CNY
Based on the latest financial reports, Fuan Pharmaceutical Group Co (300194) has net assets worth CN¥4.45 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.97 Billion) and total liabilities (CN¥1.51 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.45 Billion |
| % of Total Assets | 74.64% |
| Annual Growth Rate | 44.61% |
| 5-Year Change | -3.45% |
| 10-Year Change | 105.89% |
| Growth Volatility | 302.61 |
Fuan Pharmaceutical Group Co - Net Assets Trend (2007–2024)
This chart illustrates how Fuan Pharmaceutical Group Co's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Fuan Pharmaceutical Group Co (2007–2024)
The table below shows the annual net assets of Fuan Pharmaceutical Group Co from 2007 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.40 Billion | +6.01% |
| 2023-12-31 | CN¥4.15 Billion | +5.12% |
| 2022-12-31 | CN¥3.95 Billion | +2.09% |
| 2021-12-31 | CN¥3.87 Billion | -15.13% |
| 2020-12-31 | CN¥4.56 Billion | +14.18% |
| 2019-12-31 | CN¥3.99 Billion | +8.00% |
| 2018-12-31 | CN¥3.69 Billion | -11.43% |
| 2017-12-31 | CN¥4.17 Billion | +5.22% |
| 2016-12-31 | CN¥3.96 Billion | +85.55% |
| 2015-12-31 | CN¥2.14 Billion | +25.11% |
| 2014-12-31 | CN¥1.71 Billion | -1.01% |
| 2013-12-31 | CN¥1.72 Billion | +0.25% |
| 2012-12-31 | CN¥1.72 Billion | +1.66% |
| 2011-12-31 | CN¥1.69 Billion | +502.18% |
| 2010-12-31 | CN¥281.05 Million | +72.10% |
| 2009-12-31 | CN¥163.31 Million | +47.45% |
| 2008-12-31 | CN¥110.76 Million | +1232.49% |
| 2007-12-31 | CN¥8.31 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fuan Pharmaceutical Group Co's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 84752709889.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥847.31 Million | 19.28% |
| Common Stock | CN¥1.19 Billion | 27.06% |
| Other Comprehensive Income | CN¥139.21 Million | 3.17% |
| Other Components | CN¥2.22 Billion | 50.49% |
| Total Equity | CN¥4.40 Billion | 100.00% |
Fuan Pharmaceutical Group Co Competitors by Market Cap
The table below lists competitors of Fuan Pharmaceutical Group Co ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hagerty Inc
NYSE:HGTY
|
$486.52 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
$486.53 Million |
|
Xinjiang Baodi Mining Co. Ltd. A
SHG:601121
|
$486.60 Million |
|
ITOCHU ENEX
F:96P
|
$486.72 Million |
|
momo.com Inc
TW:8454
|
$486.27 Million |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
$486.22 Million |
|
NMDC Steel Limited
NSE:NSLNISP
|
$486.20 Million |
|
Hippo Holdings Inc
NYSE:HIPO
|
$486.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fuan Pharmaceutical Group Co's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,144,805,149 to 4,395,875,171, a change of 251,070,022 (6.1%).
- Net income of 279,837,280 contributed positively to equity growth.
- Dividend payments of 84,217,397 reduced retained earnings.
- Other comprehensive income increased equity by 153,189,118.
- Other factors decreased equity by 97,738,979.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥279.84 Million | +6.37% |
| Dividends Paid | CN¥84.22 Million | -1.92% |
| Other Comprehensive Income | CN¥153.19 Million | +3.48% |
| Other Changes | CN¥-97.74 Million | -2.22% |
| Total Change | CN¥- | 6.06% |
Book Value vs Market Value Analysis
This analysis compares Fuan Pharmaceutical Group Co's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 8.84x to 1.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2007-12-31 | CN¥0.48 | CN¥4.26 | x |
| 2008-12-31 | CN¥0.46 | CN¥4.26 | x |
| 2009-12-31 | CN¥0.27 | CN¥4.26 | x |
| 2010-12-31 | CN¥0.47 | CN¥4.26 | x |
| 2011-12-31 | CN¥2.26 | CN¥4.26 | x |
| 2012-12-31 | CN¥2.18 | CN¥4.26 | x |
| 2013-12-31 | CN¥2.22 | CN¥4.26 | x |
| 2014-12-31 | CN¥2.24 | CN¥4.26 | x |
| 2015-12-31 | CN¥2.63 | CN¥4.26 | x |
| 2016-12-31 | CN¥3.39 | CN¥4.26 | x |
| 2017-12-31 | CN¥3.51 | CN¥4.26 | x |
| 2018-12-31 | CN¥3.08 | CN¥4.26 | x |
| 2019-12-31 | CN¥3.35 | CN¥4.26 | x |
| 2020-12-31 | CN¥3.45 | CN¥4.26 | x |
| 2021-12-31 | CN¥3.14 | CN¥4.26 | x |
| 2022-12-31 | CN¥3.32 | CN¥4.26 | x |
| 2023-12-31 | CN¥3.40 | CN¥4.26 | x |
| 2024-12-31 | CN¥3.77 | CN¥4.26 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fuan Pharmaceutical Group Co utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.37%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 11.70%
- • Asset Turnover: 0.40x
- • Equity Multiplier: 1.36x
- Recent ROE (6.37%) is below the historical average (17.36%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 118.86% | 5.74% | 1.16x | 17.92x | CN¥4.91 Million |
| 2008 | 47.66% | 23.03% | 0.98x | 2.11x | CN¥36.11 Million |
| 2009 | 58.02% | 27.94% | 1.19x | 1.75x | CN¥75.04 Million |
| 2010 | 44.77% | 26.54% | 1.34x | 1.26x | CN¥95.63 Million |
| 2011 | 5.75% | 26.56% | 0.20x | 1.10x | CN¥-70.33 Million |
| 2012 | 5.20% | 21.07% | 0.23x | 1.06x | CN¥-81.59 Million |
| 2013 | 2.25% | 10.72% | 0.19x | 1.09x | CN¥-132.05 Million |
| 2014 | 2.68% | 10.19% | 0.24x | 1.07x | CN¥-124.98 Million |
| 2015 | 3.04% | 9.17% | 0.29x | 1.16x | CN¥-148.59 Million |
| 2016 | 5.60% | 17.11% | 0.29x | 1.11x | CN¥-174.40 Million |
| 2017 | 6.83% | 13.62% | 0.45x | 1.12x | CN¥-132.21 Million |
| 2018 | -9.75% | -13.49% | 0.62x | 1.16x | CN¥-729.34 Million |
| 2019 | 7.34% | 10.53% | 0.59x | 1.19x | CN¥-106.05 Million |
| 2020 | 5.11% | 8.84% | 0.40x | 1.46x | CN¥-200.65 Million |
| 2021 | -7.95% | -12.10% | 0.43x | 1.53x | CN¥-670.32 Million |
| 2022 | 5.19% | 8.45% | 0.41x | 1.49x | CN¥-189.90 Million |
| 2023 | 5.59% | 8.76% | 0.44x | 1.44x | CN¥-182.61 Million |
| 2024 | 6.37% | 11.70% | 0.40x | 1.36x | CN¥-159.75 Million |
Industry Comparison
This section compares Fuan Pharmaceutical Group Co's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fuan Pharmaceutical Group Co (300194) | CN¥4.45 Billion | 118.86% | 0.34x | $486.41 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |